Articles By Wayne Koberstein, Executive Editor

CtW_AMO_Ibraheem Mahmood_450x300
Companies To Watch: AMO Pharma
AMO Pharma is applying “de-risked” compounds as potential medicines for rare diseases in brain development.  Continue Reading..
  • Coming Out Of Stealth Mode: What To Know And Do
    8/2/2021

    In Part two of this two-part series, we look at what companies should do to make the exit from stealth mode an effective exchange with the outside world — how to identify and reach investors, influencers, and stakeholders in a company’s pursuit of new treatments for diseases, from rare conditions to widespread medical challenges, some at the scale of public health.

  • The Collective Benefits Of A Collaborative CFO
    7/1/2021

    Terry Coelho, CFO, works as a team member, not just a finance manager, at BioDelivery Sciences.

  • Companies To Watch: NervGen Pharma
    7/1/2021

    NervGen Pharma is going beyond preclinicals to human trials for a drug that could repair and regrow neurons.

  • Coming Out Of Stealth Mode: What To Know And Do
    7/1/2021

    Five CEOs discuss their experiences with stealth mode transitions. They address when and how a company should turn away from that introspective state and show itself to the world.

  • Companies To Watch: IM Therapeutics
    6/1/2021

    Our company to watch this month is IM Therapeutics, which focuses on developing small molecule therapies for Type 1 diabetes, celiac disease, and other autoimmune conditions.

  • Synergistic COVID Therapy Development
    5/3/2021

    From the outside, it may look as if Biophytis took a sharp turn from its focus on aging to address Covid. But look again.

  • Companies To Watch: Lyra Therapeutics
    5/3/2021

    Our company to watch this month, Lyra Therapeutics, is focused on controlling chronic ENT conditions with precise drug elution and long action.

  • 180 Life Sciences: Deliberately Seeking Serendipity
    4/1/2021

    At 180 Life Sciences, veterans of the old-pharma world are building a small bio enterprise focused evenly on scientific and market opportunities in the inflammation space.

  • Companies To Watch: Carisma Therapeutics
    4/1/2021

    Carisma Therapeutics is a private company developing CAR-M (chimeric antigen receptor macrophage) as an alternative to CAR-T (CAR-T cell) and potential treatment for solid tumors rather than just liquid cancers.

  • Canadian COVID Vax Comes Forward
    3/1/2021

    Long before the Warp Speed race, vaccines were a global business more characterized by collaboration than competition. In concert with its national regulator, Health Canada, IMV, Inc. could make world history with its approach to COVID vaccination.

  • Companies To Watch: PhaseBio
    3/1/2021

    PhaseBio is a small, public company aiming to enter a large-market therapeutic area: cardiovascular.

  • Companies To Watch: Akero Therapeutics
    2/1/2021

    Companies To Watch: Akero Therapeutics - Test-proofing a new metabolism drug to beat the liver disease, NASH

  • RNA’s Rousing New Adventure
    2/1/2021

    Dicerna shows how the multitude of “co-opportunities” of COVID in the RNA space has further encouraged companies to exploit the unique attributes of those approaches well beyond dealing with the immediate viral threat.

  • Going Public In Mid-Pandemic
    1/4/2021

    Just as the COVID pandemic hit, Timber Pharma was planning on going public. But that wasn’t the only challenge the company faced in the months ahead.

wayne koberstein

Wayne Koberstein


Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.